Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EPS (Weighted Average and Diluted) (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.36 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 71.43% year-over-year to -$0.36, compared with a TTM value of -$1.88 through Sep 2025, down 27.03%, and an annual FY2024 reading of -$1.55, up 18.85% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.36 for Q3 2025 at Barinthus Biotherapeutics, up from -$0.52 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.71 in Q4 2021 and bottomed at -$1.9 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.35, with a median of -$0.43 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 1400.0% in 2021, then soared 269.23% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.71 in 2021, then plummeted by 177.46% to -$0.55 in 2022, then increased by 20.0% to -$0.44 in 2023, then dropped by 15.91% to -$0.51 in 2024, then increased by 29.41% to -$0.36 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BRNS at -$0.36 in Q3 2025, -$0.52 in Q2 2025, and -$0.49 in Q1 2025.